ArticleClinicoEconomics and outcomes research : CEOR2026
Impact of Delaying Disease Recurrence on Economic Burden in Patients with HER2+ Early-Stage Breast Cancer (eBC).
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to assess neoadjuvant (neo), post-neo, and adjuvant (adj) treatment (tx) patterns, recurrence rates, and the impact of recurrence timing on the cumulative cost burden among HER2+ early breast cancer (eBC) patients. Methods: Merative™ MarketScan Results: A total of 3745 patients with HER2+ eBC were included in the study (mean age 53.7 yrs): 57.4% (n=2151) with adj tx only, 40.2% (n=1504) with neo and post-neo tx, 1.9% (n=70) with surgery only, and 0.5% (n=20) neo tx only. During follow-up (median duration post-surgery: 2 years), the rate of first recurrence was highest for surgery only (70.0%) and similar for adj only (16.0%) and neo and post-neo tx (14.3%) cohorts. GLM showed that the cumulative cost burden following surgery was higher among patients who experienced the first recurrence in <12 months vs no recurrence ($348,834 vs $265,279). Patients with chemo only as adj tx had a higher cumulative cost burden (Risk Ratio [RR] 1.28; p <0.001) than those with HER2 targeted treatment; and patients with neo tx had a lower cost burden (RR 0.85, p <0.001) compared with those with no neo tx. Conclusion: Delays in recurrence were associated with lower cumulative cost burden. Study findings highlight that the appropriate use of more effective HER2 targeted treatments that delay the time of first recurrence in neoadjuvant and adjuvant settings may improve patient outcomes and reduce the long-term healthcare burden associated with BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.